0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Multidisciplinary management

Session 4: Difficult to treat patients

Maren Eriksen

Headache Nurse, MHD, The Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Denmark

Previous

Combining preventative therapies

Next

Safety, tolerability and possible interactions of the MAbs

You Might Also Like

Related Embedded Video Item Thumbnail New EHF guideline on the use of MAb’s for migraine prevention
Related Embedded Video Item Thumbnail Patient FAQs & demands and how to address
Related Embedded Video Item Thumbnail Safety, tolerability and possible interactions of the MAbs
Related Embedded Video Item Thumbnail Epidemiology
Related Embedded Video Item Thumbnail Combining preventative therapies

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128